Subventions financées

Amyotrophic lateral sclerosis (ALS) is a debilitating and terminal disease.

Current biomarkers of ALS used by clinicians to help care for ALS patients have many drawbacks that may include cost, accessibility, and invasiveness of procedures.

A G4C2 repeat expansion in C9orf72 (chromosome 9 open reading frame 72), a gene of unclear function, is the most frequent genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (C9-ALS/FTD).

TDP-43 is an essential DNA/RNA binding protein at the epicenter of Amyotrophic Lateral Sclerosis (ALS).

Brain derived neurotrophic factor (BDNF) is well recognized for its neuroprotective functions, via activation of its high affinity receptor, tropomysin related kinase B (TrkB).

While significant efforts have been made worldwide, the development of an effective therapy to significantly slow or halt amyotrophic lateral sclerosis (ALS) progression has remained elusive.

We are testing a new digital mental health solution for physicians to better manage the treatment of depression.

Postpartum mental health problems, including depression and anxiety, affect 15-20% of people and are a serious public health concern.

Optimization of Prefrontal Theta-Burst Stimulation to Treat Depression: A Bench to First-in-Human Study

By 2050, over 1 million Canadians will suffer from depression; many of whom will not respond to traditional antidepressant medication, known to as treatment resistant depression (TRD).